Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 526 to 540 of 1688 results for carers

  1. Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]

    Awaiting development [GID-TA11040] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822

    Awaiting development [GID-TA11229] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Orforglipron for managing overweight and obesity TS ID 12102

    Awaiting development [GID-TA11650] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]

    Awaiting development [GID-TA11625] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. RWE Navigator feedback

    Health technology assessment agency Regulator Patient or carer Clinicians Academic Other (please specify)

  6. Sunlight exposure: risks and benefits (NG34)

    This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.

    NICE guideline
    Published
    9 February 2016
    View recommendations

    Sections for NG34

  7. Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392

    Awaiting development [GID-TA11085] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769

    Awaiting development [GID-TA11088] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer TS ID 12068

    Awaiting development [GID-TA11599] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [TS ID 12095]

    Awaiting development [GID-TA11626] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.

    Highly specialised technologies guidance
    Published
    27 November 2019
    View recommendations

    Sections for HST12

  12. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]

    In development [GID-TA10877] Expected publication date: 08 January 2025

    Technology appraisal guidance
    In development

  13. Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

    In development [GID-TA10252] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  14. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis TS ID 12050

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

    In development [GID-TA11431] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development